Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome
dc.contributor.author | Kaldırım, Havva | |
dc.contributor.author | Kürşat, Atalay | |
dc.contributor.author | Nacaroğlu, Şenay Aşık | |
dc.contributor.author | Yazgan, Serpil | |
dc.contributor.author | Kırgız, Ahmet | |
dc.date.accessioned | 2024-08-04T19:53:29Z | |
dc.date.available | 2024-08-04T19:53:29Z | |
dc.date.issued | 2020 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Purpose: To evaluate the effectiveness of intravitreal injections of dexamethasone (DEX) implant in patients with pseudophakic cystoidmacular edema (PCME) or Irvine-Gass Syndrome (IGS).Material and Methods: Patients with ME secondary to uncomplicated cataract surgery who underwent single intravitreal injections of DEXimplant from January 2015 to January 2017 were retrospectively reviewed. The patients were examined at base-line and day 1, week 1, month1, 3, 6 and 12 after intravitreal injection. All patients underwent a complete ophthalmic evaluation, including biomicroscopy, best-correctedvisual acuity (BCVA), intraocular pressure by applanation tonometry, and central macular thickness (CMT) measurement with a spectraldomainoptical coherence tomography (SD-OCT).Results: Nineteen eyes of 18 patients were evaluated. The alteration of mean BCVA and CMT were statistically signifi cantly better than baselinevalues at fi rst, third, sixth and twelfth months (p< 0.001). At 1st week, 1st month and 3rd month intraocular pressure (IOP) values signifi cantlyhigher than baseline (p=0.001, p=0.006, p=0.001, respectively). At 6th month and 12th month IOP values not signifi cantly different at baseline(p=0.506, p=0.650).Conclusion: Both BCVA and mean CMT had signifi cantly improved from baseline values after treatment with single doz intravitreal DEXimplant in patients with IGS. | en_US |
dc.identifier.doi | 10.37845/ret.vit.2020.29.19 | |
dc.identifier.endpage | 110 | en_US |
dc.identifier.issn | 1300-1256 | |
dc.identifier.issn | 2717-7149 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 105 | en_US |
dc.identifier.trdizinid | 458645 | en_US |
dc.identifier.uri | https://doi.org/10.37845/ret.vit.2020.29.19 | |
dc.identifier.uri | https://search.trdizin.gov.tr/yayin/detay/458645 | |
dc.identifier.uri | https://hdl.handle.net/11616/89838 | |
dc.identifier.volume | 29 | en_US |
dc.indekslendigikaynak | TR-Dizin | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Retina-Vitreus | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome | en_US |
dc.type | Article | en_US |